Since treatment (30 months ago) there have been no further respiratory collapses and temperature regulation has returned to normal. Anterior pituitary function has remained unchanged and puberty has been induced. Repeat NMR scan 12 months after the radiotherapy showed shrinkage in the size of the tumour.
Discussion
The combination of hypopituitarism, obesity and disturbance of temperature and water balance was strongly suggestive of a hypothalamic lesion. In addition, this patient displayed an unusual respiratory disorder. Respiratory disorders associated with hypothalamic lesions have been reported and have led to the term 'Pickwickian' syndrome", Although the patient had a restrictive ventilatory defect and hypoventilated at night, we believe that the episodes of respiratory failure had a different aetiology.
Because of the rapid onset of pulmonary oedema, the normal cardiac function and pulmonary pressures, we suggest that the aetiology of the pulmonary oedema was neurogenic. Hypothalamic involvement in neurogenic pulmonary oedema is common; animal studies have shown that electrolytic lesions to the base of the preoptic nucleus produce pulmonary oedema in rats':". The presence of pulmonary oedema in these animals seemed to predispose them to developing pneumococcal pneumonia. In man, trauma, haemorrhage and convulsive disorders have been associated with neurogenic pulmonary oedemas. To our knowledge, the only cerebral tumour associated with this type of presentation has been a cerebellar astrocytoma 6 • Despite the clinical picture and investigations suggesting a hypothalamic lesion, we were unable to demonstrate it, even with high-resolution CT scanning. High-resolution CT scans require different tissue density or blood flow to identify a lesion, whereas NMR scans measure differences in water content. Presumably with a slowly growing tumour, blood flow is not increased, hence the normal CT scan appearance.
At all ages in childhood, hypothalamic tumours are the commonest cause of acquired diabetes insipidus 7 • Craniopharyngiomas are the commonest, but germinomas and gliomas need also to be considered. It was on this basis that radiotherapy was given. This case highlights the need to use multiple imaging techniques in patients suspected of having hypothalamic disease. Obesity is a common condition, with 14% of the UK population 1 having a body weight more than 20% above the ideal. The volume of distribution of certain drugs may be quite different in the obese patient. We describe an obese patient who developed cardiac failure after doxorubicin (Adriamycin) therapy, despite cautious reduction of the calculated dose.
Case report
An obese woman presented at the age of 40 with invasive adenocarcinoma of the right breast. General examination, electrocardiogram, liver and bone isotope scan were normal at that time. She had no history of cardiac disease.
Right simple mastectomy and bilateral oophorectomy were carried out, followed by three courses of adjuvant thiotepa and methotrexate. She remained well for 3t years, when she developed a right supraclavicular lymph node recurrence of the carcinoma which was proven histologically. Investigations showed mildly deranged liver function tests (aspartate aminotransferase 90 iu/I, alanine aminotransferase 150 iu/I, lactic dehydrogenase 395 iu/l, gammaglutamyl transpeptidase 86 iu/l), but the bilirubin was normal at 13/lmol/!. ECG, liver and bone scan remained normal.
Cytotoxic treatment was planned with intravenous doxorubicin 60 mg/m 2 and vincristine 1 mg/m 2 , maximum 2 mg. Her height was 154 em and weight 101.8 kg, giving a calculated surface area of 1.95 m 2 and a calculated dose of doxorubicin of 117 mg. Although plasma bilirubin was normal, it was considered prudent to reduce the doxorubicin dose to 100mg in three divided doses over 3 days because of the abnormal liver enzymes. Three courses of intravenous doxorubicin 100mg and vincristine 2 mg were given at four-week intervals with weekly reviews in the outpatient department. The treatment was tolerated well by the patient and there was no significant myelosuppression, but 5 days after the fourth course Idiopathic hypoparathyroidism is rare but affects approximately one in 4000 people", Up to 58% will have associated Addison's diseaae''. The hypoparathyroidism often develops first but both diagnoses are usually made before the age of 20 years. A case is reported in whom the onset of adrenocortical failure and its treatment had profound effects on the serum calcium concentration. Cancer 1980; 45:2231-9 7 Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm 1974; 8:650-5 Tables listed in Documenta Geigy also give desirable weights based on sex, height and frame size. In our patient, the calculated surface area was 1.95m 2 and the cumulative dosage administered was therefore 241 mg/m", Using the above calculation, the ideal surface area would have been 1.4 m 2 , resulting in an approximate 30% reduction in dose. Further reduction might have been made in view of the abnormal liver function.
A 15-year-old schoolgirl was referred in 1980with predominantly gastrointestinal symptoms: weight loss, nausea, vomiting, diarrhoea with pale faeces, and vague central abdominal pain. She also complained of dizziness, 'funny turns' and breathlessness. Her supine BP was 100/70mmHg with a sinus tachycardia. She had been below the 3rd centile for her height since age 8 and for weigh t since age 12;she was prepubertal.
of treatment she was admitted acutely with dyspnoea, orthopnoea and peripheral oedema. There was no preceding chest pain. The patient had by then received 470 mg doxorubicin (241mg/m").
Examination revealed a tachycardia of 120 per minute, elevation of the jugular venous pressure, cardiomegaly with a third heart sound, basal crepitations and sacral oedema. Chest X-ray confirmed cardiomegaly with left ventricular failure and an ECG showed new T-wave flattening throughout all leads. Serial ECGs and cardiac enzymes did not show the pattern associated with myocardial infarction. It was therefore concluded that this was a doxorubicininduced cardiomyopathy. The patient continued to deteriorate despite diuretic therapy and died 4 days after admission.
Discussion
This case history is disturbing because a patient who received cautious treatment with doxorubicin died of cardiac toxicity at a cumulative dose of only 241 mg/m 2 • The risk of cardiotoxicity with doxorubicin 2 is considered to increase from 3% at 400 mg/m 2 to 7% at 550 mg/m 2 and 18% at 700mg/m 2 • We consider that obese patients could develop cardiotoxicity if doses are calculated on the basis of total body weight because of the pharmacokinetics ofthe drug.
Our patient had deranged liver function tests before starting cytotoxic treatment, but the plasma bilirubin was normal. A 50% dose reduction is suggested when bilirubin levels exceed 1.2 mg/100 ml (20pmol/l)3, but no recommendations are made on the drug data sheet for dose reduction when there are liver enzyme abnormalities. Brenner et al." have shown that doxorubicin pharmacokinetics are unaffected by liver function abnormalities, although this does not exclude an effect upon tissue concentrations. In our patient the calculated dose was reduced from 117mg to 100mg as a precaution in view of the liver function abnormalities. We do not consider that the cardiotoxicity can be explained on liver function abnormalities alone, although they may have contributed to it.
In the obese patient the smaller ratio of body water and muscle mass to total body weight and the greater proportion of fat may lead to changes in the drug partitioning of polar lipid-insoluble drugs like doxorubicin. The drug has a high apparent volume of distribution (1780±1120l/m 2 ) 5, indicating that doxorubicin is concentrated in tissues as well as body water. Lee et al. 6 have shown that at 1.5 to 5 hours after an intravenous bolus of 30 mg/m 2 doxorubicin, the liver concentrates the drug most intensely (2.3-19.8pg/g), with lesser concentration occurring in tumour tissue, lymph nodes, muscle and bone marrow. Fat showed the lowest concentration of the drug (0.03-0.33Ilg/g). We suggest that in our obese patient, higher blood and heart levels of drug occurred because of a dosage calculation based on total body weight and hence an overestimation of total body water. Liver function abnormalities (which can occur in obesity without other pathology) may exacerbate this problem. We therefore suggest that since obesity is so common, doxorubicin and other lipid-insoluble drugs with a narrow therapeutic index should be administered on the basis of the patient's ideal surface area or weight.
Ideal body weight may be calculated using height and weight by Devine's 7 method:
